{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:31:05Z","timestamp":1793647865715,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jaad.2021.03.050","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T14:01:23Z","timestamp":1616248883000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results"],"prefix":"10.1016","volume":"85","author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Ann","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Craiglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2021.03.050_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archderm.1992.01680150136027","article-title":"Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey","volume":"128","author":"Safavi","year":"1992","journal-title":"Arch Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2021.03.050_bib2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jaad.2021.03.050_bib3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.050_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2340\/0001555549180188","article-title":"Alopecia areata. A follow-up investigation of outpatient material","volume":"49","author":"Gip","year":"1969","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.050_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.03.050_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2230.1989.tb02604.x","article-title":"Juvenile versus maturity-onset\u00a0alopecia areata: a comparative retrospective clinical study","volume":"14","author":"De Waard-van der Spek","year":"1989","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.03.050_bib7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4065\/70.7.628","article-title":"Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2021.03.050_bib8","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","author":"Okhovat","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.050_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.03.050_bib10","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.jaad.2021.03.050_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jaad.2021.03.050_bib13","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/jid.2010.260","article-title":"Collapse of immune privilege in alopecia areata: coincidental or substantial?","volume":"130","author":"Gilhar","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.03.050_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O'Shea","year":"2008","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.jaad.2021.03.050_bib15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2021.03.050_bib16","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.jaad.2021.03.050_bib17","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.jaad.2021.03.050_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"12","key":"10.1016\/j.jaad.2021.03.050_bib19","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"19","key":"10.1016\/j.jaad.2021.03.050_bib20","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jaad.2021.03.050_bib21","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.050_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines: part II","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.050_bib23","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1038\/jidsymp.2013.19","article-title":"Development of the alopecia areata symptom impact scale","volume":"16","author":"Mendoza","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"10.1016\/j.jaad.2021.03.050_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.050_bib25","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","article-title":"The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning","volume":"19","author":"Mendoza","year":"2018","journal-title":"J Investig Dermatol Symp Proc"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:59:01Z","timestamp":1759273141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221006010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0190962221006010"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}